Related Experiment Videos
Positive selection moments identify potential functional residues in human olfactory receptors
M S Singer1, Y Weisinger-Lewin, D Lancet
1Section of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA. mike@miris.med.yale.edu
Summary
Researchers identified key residues in human olfactory receptors (ORs) likely interacting with odor ligands. Analysis of the sixth transmembrane domain (TM6) suggests specific residues form binding sites, crucial for understanding smell perception.
Area of Science:
- Molecular biology
- Biophysics
- Sensory neuroscience
Background:
- Olfactory receptors (ORs) detect diverse odor molecules.
- Residues within transmembrane domains are implicated in forming odorant binding pockets.
- Previous studies used mutation analysis and molecular modeling to support this hypothesis.
Purpose of the Study:
- To independently test the hypothesis that transmembrane residues form the OR ligand binding pocket.
- To identify residues in the sixth transmembrane domain (TM6) of human ORs under positive selection.
- To correlate positive selection with potential ligand interaction sites.
Main Methods:
- Calculation of positive selection moments for the TM6 of human olfactory receptors.
- Analysis of identified residues for potential functional roles in ligand binding.
- Comparison with site-directed mutagenesis data from related receptors (e.g., beta-adrenergic receptor).
Main Results:
- Identified specific residues in TM6 likely under positive selection, indicating functional importance.
- Residue 622 (serine or threonine) suggested to form critical hydrogen bonds.
- A dual-serine subsite (residues 622 and 625) proposed to bind hydroxyl groups on odor ligands.
Conclusions:
- The study provides independent evidence supporting the role of TM6 residues in odorant binding.
- Specific residues, particularly 622 and 625, are highlighted as critical for ligand interaction.
- Findings have implications for future research in olfaction, including physiological studies and drug design.